Publications
Publications
Show Results For
- All HBS Web
(119,021)
- Faculty Publications (483)
- January 1994 (Revised July 1998)
- Case
Repligen Corporation: January 1992
By: Josh Lerner and David Kane
Sandford Smith, CEO of Repligen, faces the breakdown of negotiations about a proposed joint venture with a large pharmaceutical firm. He must decide whether to proceed using his firm's internal resources or whether to seek to revise the proposed collaboration. If the... View Details
- January 1994 (Revised November 2001)
- Background Note
Note on the Venture Leasing Industry, A
By: Josh Lerner
Provides an overview of venture leasing, an innovative financing mechanism that resembles both venture equity investments and bank lending. View Details
Keywords: Finance
- January 1994 (Revised April 1995)
- Case
EMC Corporation: Response to Shareholder Litigation (A)
By: Josh Lerner
EMC Corp. is the target of a shareholder class-action lawsuit for the second time. CEO, Richard Egan, must decide whether to settle the case, as is done in 96% of such cases and as EMC itself did previously, or fight the action. View Details
- January 1994 (Revised April 1994)
- Case
EMC Corporation: Response to Shareholder Litigation (B)
By: Josh Lerner
Reports EMC's decision concerning the second shareholder class-action suit and its implications. Legislative efforts to reform securities litigation are also discussed. View Details
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,... View Details
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (B1): Rights Offering Strategy
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the CEO's decision. View Details
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (B2): The Rights Offering
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the implementation of the CEO's decision. View Details
Keywords: Intellectual Property
- April 1993 (Revised February 1996)
- Supplement
ALZA and Bio-Electro Systems (C): 1988-92
By: Josh Lerner and Peter Tufano
Supplements the (A) case. Describes the aftermarket performance of the units. View Details
Keywords: Performance
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- December 1992 (Revised September 1996)
- Case
ImmuLogic Pharmaceutical Corporation (Abridged)
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The rationales for and problems of high-technology start-ups are explored. The challenges posed by "windows" for public offerings are... View Details
- October 1992 (Revised November 1997)
- Case
ImmuLogic Pharmaceutical Corporation (A): March 1991
By: Josh Lerner
ImmuLogic Pharmaceutical Corp., a development-stage biotechnology company, is considering making an initial offering of common stock. The diverse perspectives of the entrepreneur, venture capitalist, investment banker, and institutional investor are explored. Problems... View Details
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B2): Henry McCance
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised April 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B4): Phillip Gross
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (C): April 1991
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
- Teaching Interest
Owner/President Management Progam (Executive Education)
By: Josh Lerner
As business owners and entrepreneurs prepare to take their companies to the next level in a highly competitive global arena, they must be fully equipped to master a range of skills—from strategy development to financial management to team... View Details
- Teaching Interest
Private Equity and Venture Capital (Executive Education)
By: Josh Lerner
As equity markets appear to strengthen, interest rates remain low, and asset values look attractive, private equity firms are uniquely positioned to pursue new opportunities. This
- Forthcoming
- Article
The (Heterogenous) Economic Effects of Private Equity Buyouts
By: Steven J. Davis, John Haltiwanger, Kyle Handley, Ben Lipsius, Josh Lerner and Javier Miranda
The effects of private equity buyouts on employment, productivity, and job reallocation vary
tremendously with macroeconomic and credit conditions, across private equity groups, and by
type of buyout. We reach this conclusion by examining the most extensive... View Details